



ASX ANNOUNCEMENT

Imugene Granted Licence from Gene Regulator for Poultry Growth Product

Major regulatory advance as AVPMA also grants permit

30 January 2006, Sydney: Imugene Limited (ASX:IMU) has achieved one of its biggest regulatory milestones with a licence for the limited and controlled release of the Poultry Productivity Enhancer. This product has already demonstrated unprecedented weight gains in poultry of 13.75 percent and this licence by the Office of the Gene Technology Regulator (OGTR) allows Imugene to conduct further trials on the Poultry Productivity Enhancer outside full laboratory containment.

The licence was issued to Imugene after submission of an expansive technical dossier of information and data based on previous laboratory trials. The OGTR concluded that the Poultry Productivity Enhancer posed minimal risk to humans or the environment.

Imugene will now proceed with the planned trial outside of laboratory conditions to further document efficacy, minimum dosage and some further safety parameters to enable additional regulatory approvals for the first product sales. This trial is anticipated to begin in the first quarter of 2006.

“This is a major step towards commercialisation for this product. This technology is very novel and has been subject to extensive review by regulators and we have now achieved our most important regulatory progress,” said Dr Warwick Lamb, managing director of Imugene.

“In the billion dollar world poultry growth products market, Imugene’s product appears the stand-out for growth promotion, feed conversion and low cost. All without the side effects of alternatives,” said Dr Lamb.

Imugene has also successfully applied for a permit from the APVMA (Australian Pesticides and Veterinary Medicines Authority) to use the Poultry Productivity Enhancer in the first intentional release trial.

Granting of these licences demonstrate the Company’s regulatory management capability and supports the safety and efficacy of the Fowl Adenoviral technology and this first product.

Perth Office

Level 20, Allendale Square
77 St Georges Terrace
Perth WA 6000
Tel: +61 8 9440 2660
Fax: +61 8 9440 2699

ABN: 99 009 179 551

Sydney Office

Registered Office
Level 1, 14 – 20 Delhi Road
North Ryde NSW 2113
Tel: +61 2 9870 7330
Fax: +61 2 9888 9338

www.imugene.com

A further approval from each of the OGTR and the APVMA is required prior to final commercial release and product sales of the Poultry Productivity Enhancer. These approvals will be sought by Merial Limited, the global licensee for the Poultry Productivity Enhancer.

END

About Imugene

Imugene specialises in commercialising animal health products for production animals including pigs and poultry.

Imugene owns the worldwide rights to the *Fowl Adenoviral Vector Delivery System* for poultry and the *Porcine Adenoviral Vector Delivery System* for pigs. Imugene has successfully licensed the first product based on the *Fowl Adenoviral Vector Delivery System* -- the *Poultry Productivity Enhancer*.

Imugene's poultry and pig portfolio is targeting a worldwide US\$3 billion annual market with four lead vaccine products under development and a strong product pipeline. Consumer demands for disease free and residue free food will bolster Imugene's prospects.

Imugene's products safely prevent disease and reduce or eliminate antibiotics and harmful chemicals in animals. Animal antibiotics and chemicals in the human food chain have been linked to the emergence of dangerous resistant bacteria in people and food residues.

For more information please visit the Imugene Website www.imugene.com

For more information:

Dr Warwick Lamb
Managing Director
+61 2 9870 7330

Mr Graham Dowland
Executive Chairman
+61 8 9440 2660

Mr Rudi Michelson
Monsoon Communications
+61 3 9620 3333